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Aims We examined the relationship between different degrees of QRS prolongation and different QRS morphologies
and clinical outcomes in patients with heart failure, reduced ejection fraction (HF-REF), and mild symptoms in
the Eplerenone in Mild Patients Hospitalization and SurvIval Study in Heart Failure trial (EMPHASIS-HF). We also
evaluated the effect of eplerenone in these patients according to QRS duration/morphology.
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Methods
and results
Patients were categorized as: QRS duration (ms) (i) <120 (n = 1375); (ii) 120–149 (n = 517); and (iii) ≥150
(n = 383), and QRS morphology (i) normal (n = 1252); (ii) left bundle branch block (BBB) (n = 608); and (iii)
right BBB/intraventricular conduction defect (IVCD) (n = 415). The outcomes examined were the composite of
cardiovascular death or heart failure hospitalization and all-cause mortality. Both abnormal QRS duration and QRS
morphology were associated with higher risk, e.g. the rates of the composite outcome were: 10.2, 17.6, and 15.5
per 100 patient-years in the <120, 120–149, and ≥150ms groups, respectively. Eplerenone reduced the risk of
the primary outcome and mortality, compared with placebo, consistently across the QRS duration/morphology
subgroups.
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Conclusion We found that even moderate prolongation of QRS duration and right BBB/IVCD were associated with a high risk
of adverse outcomes in HF-REF. Eplerenone was similarly effective, irrespective of QRS duration/morphology.
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Introduction
The advent of CRT brought into focus the importance of QRS
prolongation on the surface 12-lead ECG and bundle branch block
(BBB) as markers of poor outcome in heart failure with reduced
ejection fraction (HF-REF).1–7 Following a series of seminal clinical
trials, there is consensus that the benefits of CRT are substantial
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. in patients with an LVEF ≤35%, a QRS duration of ≥150ms, and
LBBB QRS morphology.1–10 The benefits in patients with a QRS
duration between 120 and 150ms are less certain, especially in
patients with milder symptoms, and there is even the suggestion
that CRT might cause harm in patients without a LBBB QRS
pattern.8–15 Clearly, therefore, it is important to demonstrate that
pharmacological therapy is effective in these high-risk subgroups
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who might not benefit from CRT. We have, therefore, examined
the effect of mineralocorticoid receptor antagonist (MRA) therapy
according to QRS duration and morphology in the Eplerenone in
Mild Patients Hospitalization and SurvIval Study in Heart Failure
trial (EMPHASIS-HF).16,17
Methods
The design and results of EMPHASIS-HF have been published.16,17
EMPHASIS-HF was a multinational, randomized, double-blind trial
designed to evaluate the effect of eplerenone on mortality and
morbidity in patients with chronic systolic HF and mild symptoms.
Overall, 2737 patients (recruited from 278 centres in ∼30 countries)
with NYHA class II heart failure and an LVEF of no more than 35%
were randomly assigned to receive eplerenone (up to 50mg daily) or
placebo, added to optimal background treatment including an ACE
inhibitor or ARB and a beta-blocker, unless contraindicated. Patients
were also required to be aged at least 55 years, have a LVEF of no more
than 30% (30–35% if the ECG QRS duration was >130ms) and have a
cardiovascular hospitalization within the past 6 months or, if not hospi-
talized, an elevated BNP. Key exclusion criteria were acute myocardial
infarction, NYHA class III or IV heart failure, a serum potassium level
exceeding 5.0mmol/L, an estimated glomerular filtration rate (GFR)
of <30mL/min/1.73m2, or a need for a potassium-sparing diuretic.
The primary outcome was a composite of death from cardiovascular
causes or hospitalization for heart failure.
QRS duration and morphology
Investigators were asked to provide a report of the patient’s ECG at the
trial screening visit using a structured case report form. This form asked
the investigator to record the patient’s QRS width (in ms) in a free text
box and QRS morphology by check box. The categories of QRS mor-
phology listed were right or left BBB. There was also space for free text
if the ECG abnormality was not listed as an option on the case report
form. We used this information to divide the patients into three QRS
duration categories (<120, 120–149, and ≥150ms) and three QRS
morphology categories [no BBB, LBBB, RBBB or ‘intraventricular con-
duction defect’ (IVCD)]. The latter QRSmorphology category was cre-
ated by adding together patients with a check box completed for RBBB
and patients with a QRS duration ≥120ms but neither LBBB nor RBBB
reported on the case report form. Patients with a pacemaker (conven-
tional or a resynchronization device) were excluded in the present anal-
ysis, as were patients with implausible QRS widths (<60 and >220ms).
Clinical outcomes
The clinical outcomes of interest in this analysis were the primary
composite outcome in EMPHASIS-HF (cardiovascular death or heart
failure hospitalization) and its components, as well as death from any
cause.
Statistical analyses
Event rates for each of the outcomes of interest in each of the
QRS duration and morphology categories were calculated per 100
person-years of follow-up and also illustrated using Kaplan–Meier
curves. ..
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.. The effect of randomized treatment in each subgroup was esti-
mated using a multivariable Cox proportional hazards model adjusting
for the EMPHASIS-HF risk score.18 Interaction parameters between
randomized treatment and baseline QRS width and morphology were
included to explore whether these modified the effect of eplerenone.
The statistical significance of the interaction parameters was tested
using likelihood ratio tests.
Results
A total of 2737 patients were randomized in EMPHASIS-HF. Of
these, 401 had a pacemaker and were therefore excluded from
analysis. A further 61 patients had a missing QRS duration (n= 19)
or a QRS duration that was implausibly low (n= 28) or high
(n= 14), leaving 2275 patients for analysis. Overall, QRS duration
was<120ms in 1375 patients (60.4%), 120–149ms in 517 (22.7%),
and ≥150ms in 383 patients (16.8%) (see the Supplementary
material online, Figure S1). Investigators identified 608 patients as
having LBBB and 157 patients with RBBB. Two-thirds of patients
(1510) had no BBB. There were 258 patients with a QRS duration
≥120ms but neither LBBB nor RBBB, i.e. patients designated as
having IVCD. The median (interquartile range) QRS duration was
146 (120, 162), 140 (120, 156), and 100 (89, 120) ms in the
LBBB, RBBB/IVCD, and the no BBB groups, respectively. Of the
383 patients with a QRS duration ≥150ms, 280 (73%) had LBBB
whereas only 234 (45%) and 94 (6.8%) of the 517 and 1375 patients
with aQRS duration of 120–149ms and<120ms, respectively, had
LBBB morphology.
Baseline characteristics
Table 1a shows the baseline characteristics of patients according to
QRS duration category and Table 1b according to QRS morphology
category. Patients with a longer QRS duration were older, had
more co-morbidity and worse heart failure status, and were more
likely to be white. A non-ischaemic aetiology was associated with
a wider QRS. A broadly similar picture was seen when comparing
patients with BBB/IVCD with those without.
Clinical outcomes according to QRS
duration and morphology
Rates of the primary composite outcome and its components
(cardiovascular death and heart failure hospitalization), along with
death from any cause are shown in Table 2. As can be seen from
Table 2 (and Figures 1 and 2), both prolonged QRS duration and
abnormal QRS morphology were associated with a considerably
higher risk of the primary composite outcome. In patients with
neither abnormality, the rate of the primary outcome was ∼10 per
100 patient-years of follow-up, whereas in those with an abnormal
QRS width or shape the rate was ∼16 per 100 patient-years of
follow-up. This higher risk was seen for both of the components of
the primary composite, although the increment in risk seemed to
be greater for heart failure hospitalization than for cardiovascular
death (Table 2).
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Table 1 Baseline characteristics
(a) According to QRS duration QRS duration (ms) P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
<120 (n= 1375) 120–149 (n= 517) 150+ (n= 383)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Characteristic
Age, years 67.6 (7.3) 69.1 (7.8) 69.0 (7.8) <0.001
Male sex, n (%) 1057 (76.9) 413 (79.9) 275 (71.8) 0.02
Race, n (%) 0.02
White 1097 (79.8) 433 (83.8) 326 (85.1)
Black 37 (2.7) 10 (1.9) 6 (1.6)
Asian 198 (14.4) 60 (11.6) 33 (8.6)
Other 43 (3.1) 14 (2.7) 18 (4.7)
Heart rate, b.p.m. 74.5 (16.4) 73.3 (15.8) 71.7 (14.1) 0.008
Blood pressure, mmHg
Systolic 125.6 (16.7) 123.8 (17.0) 122.5 (16.7) 0.002
Diastolic 76.1 (10.1) 73.7 (9.5) 73.3 (10.4) <0.001
Left ventricular ejection fraction, % 26.4 (4.1) 26.2 (4.9) 25.2 (5.5) <0.001
Body mass index 27.6 (4.9) 27.4 (4.6) 27.3 (4.8) 0.54
Principal cause of heart failure, n (%) <0.001
Ischaemic 996 (72.4) 364 (70.4) 222 (58.0)
Non-ischaemic 375 (27.3) 153 (29.6) 161 (42.0)
Unknown 4 (0.3) 0 (0.0) 0 (0.0)
Heart failure duration, years 3.8 (5.2) 5.2 (6.1) 5.3 (6.0) <0.001
Medical history, n (%)
Hospitalization for heart failure 661 (48.1) 292 (56.5) 218 (56.9) <0.001
Hypertension 949 (69.0) 338 (65.4) 245 (64.0) 0.10
Angina 632 (46.0) 229 (44.3) 150 (39.2) 0.06
Previous MI 711 (51.7) 283 (54.7) 164 (42.8) 0.001
PCI 273 (19.9) 109 (21.1) 77 (20.1) 0.84
CABG 195 (14.2) 114 (22.1) 62 (16.2) <0.001
Atrial fibrillation or flutter 412 (30.0) 150 (29.0) 93 (24.3) 0.09
Left bundle branch block 94 (6.8) 234 (45.3) 280 (73.1) <0.001
Diabetes 451 (32.8) 166 (32.1) 105 (27.4) 0.13
Stroke 126 (9.2) 60 (11.6) 31 (8.1) 0.16
ICD 97 (7.1) 50 (9.7) 57 (14.9) <0.001
Haemoglobin, g/dL 13.9 (1.5) 13.7 (1.5) 13.9 (1.6) 0.20
Serum creatinine, mg/dL 1.11 (0.29) 1.16 (0.32) 1.15 (0.30) 0.003
Estimated GFR, mL/min/1.73m2 74.1 (22.8) 69.0 (20.2) 68.6 (19.9) <0.001
Estimated GFR <60mL/min/1.73m2, n (%) 394 (28.7) 171 (33.2) 137 (36.0) 0.01
Serum potassium, mmol/L 4.3 (0.4) 4.3 (0.4) 4.3 (0.5) 0.32
Medication at randomization visit, n (%)
Diuretic 1138 (82.8) 439 (84.9) 337 (88.0) 0.04
ACE inhibitor 1145 (83.3) 416 (80.5) 302 (78.9) 0.09
ARB 230 (16.7) 108 (20.9) 83 (21.7) 0.03
ACE inhibitor or ARB 1316 (95.7) 492 (95.2) 360 (94.0) 0.37
Beta-blockers 1200 (87.3) 452 (87.4) 318 (83.0) 0.08
Digoxin 247 (18.0) 98 (19.0) 85 (22.2) 0.17
Lipid-lowering drug 825 (60.0) 320 (61.9) 234 (61.1) 0.74
Aspirin 845 (61.5) 299 (57.8) 225 (58.7) 0.29
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(b) According to BBB category BBB category P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Normal (n=1252) RBBB/IVCD (n= 415) LBBB (n= 608)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Characteristic
Age, years 67.6 (7.3) 68.8 (7.7) 69.0 (7.8) <0.001
Male sex, n (%) 959 (76.6) 346 (83.4) 440 (72.4) <0.001
Race, n (%) 0.04
White 995 (79.5) 345 (83.1) 516 (84.9)
Black 30 (2.4) 10 (2.4) 13 (2.1)
© 2015 The Authors
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Table 1 Continued
(b) According to BBB category BBB category P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Normal (n=1252) RBBB/IVCD (n= 415) LBBB (n= 608)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Asian 185 (14.8) 42 (10.1) 64 (10.5)
Other 42 (3.4) 18 (4.3) 15 (2.5)
Heart rate, b.p.m. 74.2 (16.3) 72.6 (15.0) 73.5 (15.7) 0.17
Blood pressure, mmHg
Systolic 125.9 (16.5) 122.8 (16.2) 123.4 (17.6) <0.001
Diastolic 76.2 (10.0) 73.4 (9.6) 73.8 (10.3) <0.001
Left ventricular ejection fraction, % 26.4 (4.1) 26.5 (4.7) 25.4 (5.2) <0.001
Body mass index 27.6 (5.0) 27.7 (4.5) 27.2 (4.8) 0.14
Principal cause of heart failure, n (%) <0.001
Ischaemic 912 (72.8) 312 (75.2) 358 (58.9)
Non-ischaemic 337 (26.9) 102 (24.6) 250 (41.1)
Unknown 3 (0.2) 1 (0.2) 0 (0.0)
Heart failure duration, years 3.8 (5.1) 5.4 (6.4) 5.0 (5.7) <0.001
Medical history, n (%)
Hospitalization for heart failure 587 (46.9) 227 (54.7) 357 (58.7) <0.001
Hypertension 862 (68.8) 280 (67.5) 390 (64.1) 0.13
Angina 584 (46.6) 181 (43.6) 246 (40.5) 0.04
Previous MI 656 (52.4) 244 (58.8) 258 (42.4) <0.001
PCI 252 (20.1) 98 (23.6) 109 (17.9) 0.08
CABG 180 (14.4) 104 (25.1) 87 (14.3) <0.001
Atrial fibrillation or flutter 368 (29.4) 133 (32.0) 154 (25.3) 0.05
Diabetes 401 (32.0) 131 (31.6) 190 (31.3) 0.94
Stroke 113 (9.0) 51 (12.3) 53 (8.7) 0.11
ICD 87 (7.0) 53 (12.8) 64 (10.5) <0.001
Haemoglobin, g/dL 13.9 (1.5) 13.8 (1.5) 13.8 (1.5) 0.36
Serum creatinine, mg/dL 1.11 (0.29) 1.17 (0.32) 1.14 (0.30) <0.001
Estimated GFR, mL/min/1.73m2 74.3 (22.8) 70.1 (21.6) 68.6 (19.4) <0.001
Estimated GFR <60mL/min/1.73m2, n (%) 354 (28.4) 134 (32.4) 214 (35.4) 0.007
Serum potassium, mmol/L 4.3 (0.4) 4.3 (0.4) 4.3 (0.4) 0.34
Medication at randomization visit, n (%)
Diuretic 1032 (82.4) 345 (83.1) 537 (88.3) 0.004
ACE inhibitor 1045 (83.5) 326 (78.6) 492 (80.9) 0.06
ARB 211 (16.9) 84 (20.2) 126 (20.7) 0.08
ACE inhibitor or ARB 1199 (95.8) 386 (93.0) 583 (95.9) 0.05
Beta-blockers 1095 (87.5) 354 (85.3) 521 (85.7) 0.40
Digoxin 225 (18.0) 82 (19.8) 123 (20.2) 0.45
Lipid-lowering drug 765 (61.1) 265 (63.9) 349 (57.4) 0.10
Aspirin 782 (62.5) 241 (58.1) 346 (56.9) 0.05
Baseline characteristics are summarised as means (standard deviations) for continuous variables and numbers (percentages) for categorical variables. A P-value of <0.05 was
considered significant.
ACE, angiotensin convertingenzyme; ARB, angiotensin receptor blocker; BBB, bundle branch block; CABG, coronary artery bypass graft; GFR, glomerular filtration rate;
ICD, implantable cardioverter defibrillator; IVCD, intraventricular conduction defect; LBBB, left bundle branch block; MI, myocardial infarction; PCI, percutaneous coronary
intervention; RBBB, right bundle branch block.
Of note, the risk observed with a widened QRS was similar
in patients with a QRS duration 120–149ms and in those with
a QRS duration ≥150ms. Likewise, the risk associated with
abnormal QRS morphology was similar in patients with LBBB and
RBBB/IVCD.
Examination of the relationship between QRS width and shape
and death from any cause revealed similar findings to those made
for the primary composite outcome. .
..
..
..
..
..
..
..
..
..
..
.. Clinical outcomes according
to randomized treatment allocation
The effect of eplerenone compared with placebo on the outcomes
of interest, according to QRS width and shape, are shown in Table 2
and Figures 3 and 4. Compared with placebo, eplerenone reduced
the risk of the primary endpoint and all-cause death, irrespective
of QRS duration and morphology (Table 2, Figure 3). Inspection
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Table 2 Endpoints according to QRS category.
Overall
(n= 2275)
Eplerenone
(n=1142)
Placebo
(n= 1133)
Adjusted hazard
ratioa (95% CI)
P-valueb
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Outcome
(i) CV death or hospitalization for heart failure
QRS category
<120ms 286 (10.2) 125 (8.5) 161 (12.0) 0.70 (0.56–0.89)
120–149ms 166 (17.6) 68 (13.8) 98 (21.7) 0.65 (0.47–0.88)
≥150ms 110 (15.5) 50 (14.0) 60 (17.1) 0.76 (0.52–1.12) 0.71
BBB category
Normal 252 (9.8) 111 (8.2) 141 (11.4) 0.72 (0.56–0.92)
RBBB/IVCD 117 (15.6) 48 (12.2) 69 (19.4) 0.58 (0.40–0.84)
LBBB 193 (17.0) 84 (14.5) 109 (19.5) 0.75 (0.56–1.00) 0.46
(ii) Cardiovascular death
QRS category
<120ms 175 (5.8) 81 (5.2) 94 (6.5) 0.82 (0.61–1.10)
120–149ms 96 (8.9) 48 (9.0) 48 (8.8) 1.00 (0.67–1.50)
≥150ms 61 (7.9) 24 (6.1) 37 (9.7) 0.54 (0.32–0.91) 0.25
BBB category
Normal 150 (5.4) 71 (5.0) 79 (5.9) 0.86 (0.63–1.19)
RBBB/IVCD 70 (8.5) 37 (8.9) 33 (8.1) 0.98 (0.61–1.57)
LBBB 112 (8.7) 45 (7.0) 67 (10.5) 0.66 (0.45–0.96) 0.32
(iii) Hospitalization for heart failure
QRS category
<120ms 181 (6.4) 70 (4.8) 111 (8.3) 0.56 (0.42–0.76)
120–149ms 113 (12.0) 42 (8.5) 71 (15.7) 0.55 (0.38–0.81)
≥150ms 76 (10.7) 40 (11.2) 36 (10.2) 1.03 (0.65–1.62) 0.06
BBB category
Normal 159 (6.2) 62 (4.6) 97 (7.9) 0.58 (0.42–0.80)
RBBB/IVCD 76 (10.1) 26 (6.6) 50 (14.0) 0.44 (0.27–0.71)
LBBB 135 (11.9) 64 (11.1) 71 (12.7) 0.86 (0.62–1.21) 0.03
(iv) All-cause death
QRS category
<120ms 204 (6.8) 97 (6.3) 107 (7.3) 0.86 (0.65–1.13)
120–149ms 108 (10.0) 51 (9.5) 57 (10.5) 0.90 (0.61–1.31)
≥150ms 70 (9.0) 27 (6.9) 43 (11.2) 0.52 (0.32–0.85) 0.26
BBB category
Normal 150 (5.4) 71 (5.0) 79 (5.9) 0.90 (0.67–1.21)
RBBB/IVCD 70 (8.5) 37 (8.9) 33 (8.1) 0.80 (0.51–1.25)
LBBB 112 (8.7) 45 (7.0) 67 (10.5) 0.68 (0.47–0.97) 0.48
Results are presented as number of patients (rate per 100 person-years).
BBB, bundle branch block; CV, cardiovascular; IVCD, intraventricular conduction defect; LBBB, left bundle branch block; RBBB, right bundle branch block
aAdjusted for EMPHASIS-HF risk score, i.e. age, sex, systolic blood pressure, estimated glomerular filtration rate, diabetes, body mass index, haemoglobin, prior heart failure
hospitalization, prior myocardial infarction/coronary artery bypass graft, and heart rate.
bP-value from interaction test.
of Figure 4 shows that the relative risk reduction with eplerenone
was similar in all ECG categories. Examination of the components
of the primary composite raised the possibility that the effect of
eplerenone on cardiovascular death might be different from the
effect on heart failure hospitalization, depending on the baseline
ECG findings. Inspection of Table 2 suggests that in patients with
the widest QRS duration and in those with LBBB, eplerenone had
no effect on heart failure hospitalization (but possibly a greater
effect on cardiovascular death) compared with the other ECG .
..
..
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..
..
..
..
. categories. The interaction P-values for heart failure hospitaliza-
tion were statistically significant or borderline significant, i.e. 0.03
and 0.06 for BBB and QRS duration, respectively. This apparent
interaction was, however, confined to QRS duration ≥150ms and
LBBB, and was not apparent for QRS duration 120–149ms or
RBBB/IVCD.
The effect of eplerenone on all-cause mortality according
to ECG category was similar to that seen for cardiovascular
mortality.
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Figure 1 Cardiovascular (CV) death or hospitalization for heart failure (HF) according to QRS duration. Event rate shown as a fraction of 1
e.g. 0.5= 50%. ms=milliseconds.
Figure 2 Cardiovascular (CV) death or hospitalization for heart failure (HF) according to QRS morphology. IVCD, intraventricular conduction
defect; LBBB, left bundle branch block; RBBB, right bundle branch block.
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Figure 3 Effect of eplerenone compared with placebo on cardiovascular (CV) death or hospitalization for heart failure (HF) according to
QRS duration. (A) QRS <120ms; (B) QRS 120–149ms; (C) QRS ≥150ms.
Discussion
The main findings in this study were that among the HF-REF
patients with mild symptoms, those with a prolonged QRS
duration or BBB experienced a considerably higher risk of the
primary composite outcome of cardiovascular death or heart
failure hospitalization, compared with patients without these ECG
abnormalities, and the MRA eplerenone reduced the risk of this
composite irrespective of patients’ QRS duration or morphology.
Additional findings of note were that QRS abnormalities were
more common in patients with a non-ischaemic aetiology and,
in this trial, QRS duration 120–149ms vs. ≥150ms and LBBB
vs. RBBB/IVCD carried similar risk relative to <120ms and no
BBB/normal QRS duration, respectively. It was also of note that
QRS prolongation/BBB seemed to be associated with an even
greater elevated risk of heart failure hospitalization than of cardio-
vascular mortality, although we cannot be sure that this difference
is real because of the low power for this analysis.
Prior reports from the Swedish Heart Failure Registry and the
EFFECT study also found that QRS prolongation was more com-
mon in non-ischaemic heart failure and that non-LBBB QRS pro-
longation was associated with at least as high unadjusted risk of ..
..
..
..
..
..
..
..
..
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..
..
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..
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..
..
..
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..
.. death as LBBB, although this has not been found in all studies.19–21
However, we do not know of any previous report of the relation-
ship between the degree of QRS prolongation and outcome. So,
while there may be concern about the value of CRT in patients with
lesser degrees of QRS prolongation and non-LBBB morphology, it
seems clear that these patients are at high risk and merit interven-
tion to reduce this risk. Our findings show that MRA therapy is
one such intervention.
The finding of a possible stronger association between QRS
abnormalities and heart failure hospitalization, compared with
death, is one of the most interesting findings in the present study.
This has been hinted at before. The Systolic Heart failure treat-
ment with the If inhibitor ivabradine Trial (SHIFT) investigators
divided their patients into those with and without LBBB, i.e.
the latter group included patients with RBBB, IVCD, and normal
QRS duration (although QRS duration was not described).22
Those with LBBB were significantly more likely to experience
the primary composite outcome of cardiovascular death or heart
failure hospitalization, compared with the remainder of patients.
The increment in risk appeared to be greater for heart failure
hospitalization than for cardiovascular mortality.22 Additional
support comes from the Enhanced Feedback For Effective Cardiac
© 2015 The Authors
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Figure 4 Effect of eplerenone compared with placebo on cardiovascular (CV) death or hospitalization for heart failure (HF) according to
QRS morphology. (A) Normal morphology; (B) non-LBBB morphology [right bundle branch block (RBBB)/intraventricular conduction defect
(IVCD)]; (C) LBBB morphology.
Treatment study (EFFECT), a study in 9487 patients admitted to
participating hospitals in Ontario with heart failure between 1999
and 2001.20 In that study, the adjusted hazard ratio for risk of death
in patients with LBBB (n= 1480) vs. no BBB (n= 6951) was 1.10
[95% confidence interval (CI) 1.02–1.18] whereas it was 1.32
(95% CI 1.20–1.46) for heart failure hospitalization. However, the
findings in that study for RBBB were not as consistent. In those
patients (n= 651), the comparable hazard ratios were 1.10 (95%
CI 0.99–1.21) and 1.10 (95% CI 0.95, 1.27), respectively. The Can-
desartan in Heart failure: Assessment of Reduction in Mortality
and morbidity Program (CHARM) also gave inconsistent findings.
Comparison of outcomes in HF-REF patients with BBB (it was not
possible to differentiate between right and left in CHARM) and
those without BBB gave an adjusted hazard ratio for cardiovascular
death of 1.32 (95% CI 1.17–1.50), whereas the hazard ratio for
heart failure hospitalization was 1.34 (95% CI 1.18–1.51).23
Another finding in the present study that should be commented
on for the sake of completeness was the possibly differential effect
of eplerenone on cardiovascular death, compared with heart fail-
ure hospitalization, in patients with LBBB/the widest QRS dura-
tion. The most likely explanation must be play of chance given the .
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.. retrospective nature of this analysis, the multiple comparisons con-
ducted, and the fact that this difference was seen for only one of
the two abnormal QRS duration and morphology categories. Inter-
pretation of the effect of treatment on heart failure hospitalization
alone has to take account of the competing risk of death (which
appeared to be reduced by the greatest amount in the groups with
the least reduction in heart failure hospitalization). In addition, we
cannot think of any other plausible mechanistic explanation for this
finding.
The most important finding in this study was that eplerenone
reduced the risk of death and hospitalization, irrespective of
patients’ QRS duration, or morphology—including abnormalities
that were associated with a high risk of adverse outcomes but
without a clear indication for CRT. These high-risk individuals had
large absolute benefits from MRA therapy, even when added to
an ACE inhibitor/ARB and beta-blocker, and although patients had
only mild symptoms.
As with any analysis of this type, there are limitations. It was
not prospectively planned, i.e. was retrospective. This plus the
examination of six subgroups and four endpoints increases the
risk of chance findings. Original ECGs were not available, and this
© 2015 The Authors
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analysis was based on information provided by investigators on
study case report forms.
In summary, we found that HF-REF patients with mild symptoms
but a prolonged QRS duration or BBB experienced a considerably
higher risk of the primary composite outcome of cardiovas-
cular death or heart failure hospitalization (and especially the
latter), compared with patients without these ECG abnormalities.
Of note, QRS duration 120–149ms vs. ≥150ms (and LBBB vs.
RBBB/IVCD) carried a similar risk relative to<120ms (and no BBB/
normal QRS duration). The MRA eplerenone reduced the risk of
death and hospitalization irrespective of patients’ QRS duration
or morphology.
Supplementary Information
Additional Supporting Information may be found in the online
version of this article:
Figure S1. Distribution curve of patients by QRS duration and
BBB morphology.
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